Navigation Links
GeoVax to Exhibit at the 2009 BIO International Convention
Date:5/11/2009

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

    WHAT:    GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
             publicly traded biopharmaceutical company developing human
             vaccines for diseases caused by HIV-1 (Human Immunodeficiency
             Virus) and other infectious agents to share their strategy for
             the future and plans to expand preventative trials, currently in
             Phase 2a, to proof-of-concept trials in 'at risk' humans and
             move therapeutic trials from non-human primate models to HIV-1
             virus infected individuals.

             Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
             and Therapeutic Approaches to a Global Pandemic"

    WHERE:   2009 BIO International Convention
             Georgia Pavilion (Booth #2817)
             Georgia World Congress Center
             Atlanta, GA

    WHEN:    May 18-21, 2009
             "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
             Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

    WHO:     Robert McNally, Ph.D., chief executive officer and president
             Mark Reynolds, chief financial officer
             Harriet Robinson, PhD, vice president of research and development
             and developer of the GeoVax vaccine

    WHY:     HIV Vaccine Awareness Day coincides with the opening of the
             conference on May 18, and Sir Elton John delivering a keynote
             address to include how biotechnology is influencing treatment and
             prevention of the diseases.  GeoVax is looking forward to sharing
             with interested partners, investors and media its progress in
             clinical trials during the last six months and its strategy for
             the future.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
3. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
4. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
5. GeoVax to Present at the BIO CEO & Investor Conference 2009
6. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
10. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
11. GeoVax Further Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical ... Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to a ... in a group of 20 patients carrying 11778, 14484 and 3460 mutations and having ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments announces ... capillary thermal mass flow technology provide exponentially more accurate mass flow data than ... of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, and ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):